Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:rifaximin
go back to main search page
Accession:CHEBI:75246 term browser browse the term
Definition:A semisynthetic member of the class of rifamycins and non-systemic gastrointestinal site-specific broad spectrum antibiotic. Used in the treatment of traveller's diarrhoea, hepatic encephalopathy and irritable bowel syndrome.
Synonyms:exact_synonym: (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-1,15-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)furo[2'',3'':7',8']naphtho[1',2':4,5]imidazo[1,2-a]pyridin-25-yl acetate
 related_synonym: Formula=C43H51N3O11;   InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1;   InChIKey=NZCRJKRKKOLAOJ-XRCRFVBUSA-N;   Rifamycin L 105;   Rifamycin L 105SV;   Rifaxidin;   SMILES=CO[C@H]1\\C=C\\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)\\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c1c(nc5cc(C)ccn15)c4c3C2=O;   Xifaxsan;   rifaximina;   rifaximine;   rifaximinun
 xref: CAS:80621-81-4;   DrugBank:DB01220;   Drug_Central:2379;   HMDB:HMDB0015351;   KEGG:D02554
 xref_mesh: MESH:C042734
 xref: PMID:23092785;   PMID:23095030;   PMID:23183443;   PMID:23216382;   PMID:23273888;   PMID:23274384;   PMID:23275147;   PMID:23303506;   PMID:23314671;   PMID:23340064;   PMID:23389621;   PMID:23445237;   PMID:23526308;   PMID:23556126;   PMID:23565181;   PMID:23589147;   PMID:23640348;   PMID:23653636;   PMID:23740443;   PMID:23798671;   PMID:23843564;   PMID:23877348;   PMID:23922656;   PMID:25214516;   PMID:25339518;   PMID:25565769;   PMID:25586470;   PMID:25641072;   PMID:25835116;   PMID:25867912;   PMID:25932262;   PMID:26028929;   PMID:26043290;   Reaxys:7790802;   Wikipedia:Rifaximin


show annotations for term's descendants           Sort by:
 
rifaximin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
increases expression
ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ABCB1A mRNA
rifaximin results in increased expression of ABCB1 mRNA
CTD PMID:21141967 PMID:22790967 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ACTA2 mRNA CTD PMID:22790967 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Apoa4 apolipoprotein A4 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of APOA4 mRNA CTD PMID:22790967 NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein] CTD PMID:21599020 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
JBrowse link
G Cd36 CD36 molecule multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CD36 protein CTD PMID:22790967 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
JBrowse link
G Cfd complement factor D multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CFD mRNA CTD PMID:22790967 NCBI chr 7:12,634,216...12,635,939
Ensembl chr 7:12,634,216...12,635,943
JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CIDEC mRNA CTD PMID:22790967 NCBI chr 4:145,377,482...145,390,497
Ensembl chr 4:145,377,431...145,390,497
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of COL1A1 mRNA CTD PMID:22790967 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7A1 protein CTD PMID:22790967 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Cyp7b1 cytochrome P450 family 7 subfamily B member 1 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7B1 protein CTD PMID:22790967 NCBI chr 2:102,701,903...102,871,257
Ensembl chr 2:102,701,903...102,871,257
JBrowse link
G Dgat2 diacylglycerol O-acyltransferase 2 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of DGAT2 mRNA CTD PMID:22790967 NCBI chr 1:164,113,459...164,143,818
Ensembl chr 1:164,113,459...164,143,818
JBrowse link
G Fabp2 fatty acid binding protein 2 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of FABP2 protein CTD PMID:22790967 NCBI chr 2:227,080,912...227,083,654
Ensembl chr 2:227,080,924...227,083,501
JBrowse link
G Ifng interferon gamma multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein] CTD PMID:21599020 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il10 interleukin 10 multiple interactions ISO [rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of IL10 protein CTD PMID:21599020 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Lta lymphotoxin alpha multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of LTA mRNA CTD PMID:22790967 NCBI chr20:4,851,889...4,854,677
Ensembl chr20:4,852,496...4,854,677
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein] CTD PMID:21599020 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of NR1H4 protein CTD PMID:22790967 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions
increases activity
increases expression
increases response to substance
ISO 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; 4,4'-hexafluorisopropylidene diphenol metabolite inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased abundance of Triglycerides; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ABCB1A mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ACTA2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of APOA4 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CD36 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CFD mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CIDEC mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of COL1A1 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP3A11 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7A1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7B1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of DGAT2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of FABP2 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of LTA mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of NR1H4 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of PPARG mRNA; [Rifaximin binds to and results in increased activity of NR1I2 protein] which results in decreased susceptibility to Trinitrobenzenesulfonic Acid; bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; Rifaximin binds to and results in increased activity of NR1I2 protein
[Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
rifaximin results in increased expression of NR1I2 mRNA
NR1I2 results in increased susceptibility to rifaximin
CTD PMID:21599020 PMID:22291955 PMID:22790967 PMID:27506419 PMID:30408883 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of PPARG mRNA CTD PMID:22790967 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of TGFB1 protein CTD PMID:21599020 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] CTD PMID:21599020 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19810
    role 19758
      biological role 19758
        antimicrobial agent 17329
          rifaximin 21
Path 2
Term Annotations click to browse term
  CHEBI ontology 19810
    subatomic particle 19808
      composite particle 19808
        hadron 19808
          baryon 19808
            nucleon 19808
              atomic nucleus 19808
                atom 19808
                  main group element atom 19696
                    p-block element atom 19696
                      carbon group element atom 19599
                        carbon atom 19588
                          organic molecular entity 19588
                            organic group 18527
                              organic divalent group 18520
                                organodiyl group 18520
                                  carbonyl group 18427
                                    carbonyl compound 18427
                                      carboxylic acid 18108
                                        carboacyl group 17369
                                          univalent carboacyl group 17369
                                            carbamoyl group 17156
                                              carboxamide 17156
                                                lactam 8032
                                                  ansamycin 835
                                                    rifamycins 390
                                                      rifaximin 21
paths to the root